FiercePharma  Mar 27  Comment 
Novo Nordisk will soon resubmit Tresiba to the FDA, earlier than once expected. The escalated timeline provided a substantial boost to Novo's shares, but the news adds pressure to Sanofi's new CEO since Tresiba targets Lantus, the French...
Wall Street Journal  Mar 27  Comment 
Shares in highly valued diabetes specialist Novo Nordisk jumped on its decision to resubmit insulin Tresiba to U.S. regulators. That is the latest thing to fall into place for the Danish company.
FierceBiotech  Mar 27  Comment 
After a surprise FDA rejection sent it back to the drawing board in 2013, Novo Nordisk is finally ready to resubmit Tresiba, a long-acting insulin with blockbuster potential.
TheStreet.com  Mar 26  Comment 
NEW YORK (TheStreet) -- Novo Nordisk A/S shares are up 7.76% to $53.69 on heavy volume in trading today after the Danish drug company announced that will refile for U.S. regulatory approval of its insulin Tresiba after early analysis of the...
Benzinga  Mar 25  Comment 
Novo Nordisk today announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset^® 1 and onset^® 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid^®...
Reuters  Mar 24  Comment 
Seven institutions, including the euro zone's largest listed bank, Santander, have presented non-binding bids for Portugal's Novo Banco, the successor to Banco Espirito...
GenEng News  Mar 24  Comment 
Bristol-Myers Squibb (BMS) said today it agreed to license from Novo Nordisk a research program focused on modulating the innate immune system as a therapy for autoimmune diseases. The price was not disclosed. The deal fits both BMS’ focus...
Wall Street Journal  Mar 24  Comment 
Benzinga  Mar 20  Comment 
Pinnacle Foods Inc. (NYSE: PF) shares reached a new 52-week high of $40.42. Pinnacle Foods' PEG ratio is 1.82. Novo Nordisk A/S (NYSE: NVO) shares rose 2.63% to touch a new 52-week high of $49.47. Novo Nordisk's trailing-twelve-month ROE is...

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki